Stay updated with breaking news from Programmed Death Ligand. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Planegg/Martinsried, May 21, 2024. Medigene AG , an immuno-oncology platform company focusing on the discovery and development of differentiated T cell immunotherapies for solid tumors and BioNTech SE...
Planegg/Martinsried, May 21, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of differentiated T cell immunotherapies for
Planegg/Martinsried, May 2, 2024. Medigene AG , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, presented superior T cell...
Planegg/Martinsried, April 25, 2024. Medigene AG , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents a...
Planegg/Martinsried, April 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid